Advancement in transporter-oriented nanoplatforms for cancer therapy

J Drug Target. 2023 Jun;31(5):456-470. doi: 10.1080/1061186X.2023.2197570. Epub 2023 Apr 5.

Abstract

Except for cell-surface receptors, a range of transporters have been exploited as targets for the delivery of novel anti-tumour nanomaterials. Transporters, which are essential for delivering nutrients for the biosynthesis of mammalian cells, are significantly expressed in a range of tumour types; their expression is mostly tissue- and site-specific. The unique functional and expression characteristics of transporters make them ideal targets for mediating the selective delivery of nanomaterials to cancer cells, thus promoting cell accumulation, and enhancing the penetration of nanomaterials into biological barriers before they can specifically target cancer cells. In this review, we discuss the unique function of cancer-related transporters in the initiation and development of tumours, as well as the use of transporter-targeted nanocarriers in tumour-targeting therapy. First, the expression of various transporters in tumorigenesis and development is reviewed; this is followed by a discussion of the latest advances in targeted drug delivery strategies based on transporter nanocarriers. Finally, we review the molecular mechanisms and targeting efficiency of transporter-mediated nanocarriers. This review provides a state-of-the-art synthesis of this discipline and will facilitate the generation of new concepts for the design of highly efficacious and tumour-targeting nanocarriers.

Keywords: Transporter; cancer-targeting; drug delivery; nanocarrier; tumour therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Carriers / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Mammals
  • Membrane Transport Proteins
  • Nanoparticles*
  • Nanostructures*
  • Neoplasms* / drug therapy

Substances

  • Membrane Transport Proteins
  • Drug Carriers